We are Zogenix.
Zogenix is committed to developing therapies that address specific clinical needs for people living with CNS and pain-related conditions who need innovative treatment alternatives to help them return to normal daily functioning.
A significant number of patients are not being effectively treated, despite the availability of current therapies. These patients deserve access to safe and effective treatments. Zogenix is committed to ensuring the safe and appropriate use of our products ... More >>
|Latest Presentations||More >>|
|04/24/15||Zogenix Closes Sale of Zohydro(R) ER Business to Pernix|
|Strategic Focus Shifts to Zogenix's High Value Late-Stage CNS Pipeline
SAN DIEGO, April 24, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that it has closed the sale of its Zohydro® ER (hydrocodone bitartrate) business to a wholly-owned subsidiary of Pernix Therapeutics Holdings, Inc. (Nasdaq:PTX) for $80 million in cash, approximately 1.68 millio... |
|03/26/15||Zogenix Announces First Patient Dosed in Relday Multi-Dose Clinical Study|
|Results Anticipated in Third Quarter 2015, Positioning Zogenix for Potential World-Wide Partnering Opportunities for Relday
SAN DIEGO, March 26, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that dosing has begun in patients enrolled in its Relday™ multi-dose Phase 1b clinical study. Relday is a proprietary, long-acting, subcutaneously injected fo... |
|03/10/15||Zogenix Announces Agreement of Sale of Zohydro(R) ER Business to Pernix for $100 Million at Closing Plus Potential Milestones of $283.5 Million|
|Enables planned implementation of new strategic focus to developing a late-stage, high-value CNS pipeline
Conference Call and Webcast on Tuesday, March 10, at 4:30 p.m. ET
$100 million in upfront consideration comprised of $30 million in cash, $20 million in Pernix common stock and a $50 million short term promissory note
$12.5 million milestone payment for approval of ZX007 abuse-deterrent extended-release hydrocodone tablet (the Altus formulation)
|03/10/15||Zogenix Reports Fourth Quarter and Full Year 2014 Financial Results|
|Conference Call and Webcast to Discuss Fourth Quarter Results and Definitive Agreement to Sell Zohydro ER to Pernix; Scheduled for Today, March 10, at 4:30 p.m. ET
Clinical and Regulatory Update
Received FDA approval for new formulation of Zohydro® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, with BeadTek™
On track to begin Phase 3 clinical study for ZX008 (orphan drug candidate for Dravet syndrome) in the third quarter 2015; data expected in 2016
Enrolled ... |
|There are currently no events scheduled.|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.